BioCryst Pharmaceuticals
BCRX
#4833
Rank
ยฃ1.57 B
Marketcap
ยฃ6.17
Share price
0.62%
Change (1 day)
18.13%
Change (1 year)

BioCryst Pharmaceuticals (BCRX) - Total liabilities

Total liabilities on the balance sheet as of June 2026 : ยฃ0.76 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's total liabilities are ยฃ0.76 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BioCryst Pharmaceuticals - Total liabilities on balance sheet (from 2001 to 2026)

Total liabilities by year

Year Total liabilities Change
2025-12-31ยฃ0.47 B-38.93%
2024-12-31ยฃ0.77 B0.88%
2023-12-31ยฃ0.76 B9.34%
2022-12-31ยฃ0.69 B35.56%
2021-12-31ยฃ0.51 B98.3%
2020-12-31ยฃ0.25 B148.51%
2019-12-31ยฃ0.10 B35.9%
2018-12-31ยฃ76.89 M9.98%
2017-12-31ยฃ69.91 M-2.26%
2016-12-31ยฃ71.53 M42.04%
2015-12-31ยฃ50.36 M28.04%
2014-12-31ยฃ39.33 M29.78%
2013-12-31ยฃ30.3 M-15.39%
2012-12-31ยฃ35.81 M-17.4%
2011-12-31ยฃ43.36 M52.34%
2010-12-31ยฃ28.46 M-17.63%
2009-12-31ยฃ34.55 M32.37%
2008-12-31ยฃ26.1 M-33.34%
2007-12-31ยฃ39.16 M62.1%
2006-12-31ยฃ24.16 M2.11%
2005-12-31ยฃ23.66 M1349.44%
2004-12-31ยฃ1.63 M77.17%
2003-12-31ยฃ0.92 M26.07%
2002-12-31ยฃ0.73 M-53.57%
2001-12-31ยฃ1.57 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Gilead Sciences
GILD
ยฃ28.42 B 3,616.68%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
ยฃ44.61 B 5,733.80%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
ยฃ1.25 B 64.08%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
ยฃ0.63 B-17.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
ยฃ0.86 B 13.25%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
ยฃ51.21 M-93.30%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
ยฃ0.8 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
ยฃ7.85 M-98.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
ยฃ0.58 B-23.39%๐Ÿ‡บ๐Ÿ‡ธ USA